Skip to main content
Clinical Trials/JPRN-UMIN000005853
JPRN-UMIN000005853
Recruiting
未知

Randomized Phase 2 Trial of Inhaled Furosemide on the dyspnea associated with Cancer - Randomized Phase 2 Trial of Inhaled Furosemide on the dyspnea associated with Cancer

Chiba University Hospital0 sites60 target enrollmentJuly 1, 2011

Overview

Phase
未知
Intervention
Not specified
Conditions
Dyspnea associated with Cancer
Sponsor
Chiba University Hospital
Enrollment
60
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2011
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • I. The first stage 1\) Hypersensitivity reactions to furosemide, opioids and sulfonamide derivatives 2\) Severe heart failure, respiratory disease with unstable dyspnea 3\) Neurological, mental impairment with the difficulty of collecting data 4\) Drug abuse, drug dependence 5\) Pregnancy, lactation II. The second stage 1\) Inability to take oral rapid onset morphine 2\) Pain score above 3 3\) Severe hypertention(SBP \>\= 180mmHg or DBP \>\= 110mmHg) 4\) Liver failure, renal failure AST(GOT) \>\= 100IU/L ALT(GPT) \>\= 100IU/L T.bil \>\= 2\.0mg/dL eGFR \<\= 30 mL/hr 5\) Severe respiratory failure or the administration of oxygen with flow rate of 10L/min or more 6\) Ineligible condition for study in physician's judge 7\) The change in prescription of opioid, steroids and anxiolytics within 2 days prior to study 8\) The change in the chemotherapy within 7 days prior to study

Outcomes

Primary Outcomes

Not specified

Similar Trials